Evidence map›Paper›PMID 38277493›Full record

ArticleJournal of natural products2024

Previously Uncharacterized Variants, OCF-E-OCF-J, of the Antifungal Occidiofungin Produced by

Nopakorn Hansanant, Kevin Cao, Abraham Tenorio, Thushinari Joseph, Min Ju, Noah McNally, Evangel Kummari, McKinley Williams, Andrew Cothrell, Andrew R Buhrow and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of natural products, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Current issues in molecular biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Nopakorn HansanantDepartment of Biology, Texas A&M University, College Station, Texas 77843, United States.
Kevin CaoSano Chemicals Incorporated, Bryan, Texas 77803, United States.
Abraham TenorioSano Chemicals Incorporated, Bryan, Texas 77803, United States.
Thushinari JosephDepartment of Biology, Texas A&M University, College Station, Texas 77843, United States.
Min JuDepartment of Biology, Texas A&M University, College Station, Texas 77843, United States.
Noah McNallyDepartment of Biology, Texas A&M University, College Station, Texas 77843, United States.
Evangel KummariDepartment of Biology, Texas A&M University, College Station, Texas 77843, United States.
McKinley WilliamsDepartment of Biology, Texas A&M University, College Station, Texas 77843, United States.ORCID 0000-0002-8494-2315
Andrew CothrellDepartment of Biology, Texas A&M University, College Station, Texas 77843, United States.
Andrew R BuhrowDepartment of Biology, Texas A&M University, College Station, Texas 77843, United States.
Ronald ShinCentral Alabama High-Field NMR Facility, Structural Biology Shared Facility, Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294-1240, United States.
Ravi OruguntySano Chemicals Incorporated, Bryan, Texas 77803, United States.
Leif SmithDepartment of Biology, Texas A&M University, College Station, Texas 77843, United States.ORCID 0000-0002-0876-7260
Texas A&M University · USUniversity of Alabama at Birmingham · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
Preclinical Development of OCF001 for Treatment of Yeast InfectionsR42AI131792 · NIAID · SANO CHEMICALS, INC · PI SMITH, JAMES LEIF · 2019 to 2021
$2.9M
800 MHz NMR Spectrometer for the Central Alabama High-Field NMR FacilityS10RR022994 · NCRR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KRISHNA, NEPALLI RAMA · 2009 to 2009
$2.0M
Lead Compound Discovery from Engineered Analogs of OccidiofunginR41AI131792 · NIAID · SANO CHEMICALS, INC · PI SMITH, JAMES LEIF · 2017 to 2017
$225k
NCI NIH HHS P30 CA013148NCRR NIH HHS S10 RR022994NIAID NIH HHS R41 AI131792NIAID NIH HHS R42 AI131792
6 · The paper itself

Abstract

The rise of multidrug resistant fungal infections highlights the need to identify and develop novel antifungal agents. Occidiofungin is a nonribosomally synthesized glycolipopeptide that has a unique mechanism of action, disrupting actin-mediated functions and inducing cellular apoptosis. Antifungal activity has been observed in vitro against various fungal species, including multidrug resistant

Indexed as

Antifungal AgentsBurkholderiaGlycopeptidesPeptides, CyclicAnimalsCarboxylic AcidsMiceMicrobial Sensitivity TestsAntifungal AgentsCarboxylic AcidsGlycopeptidesoccidiofunginPeptides, Cyclic

Identifiers

PMID38277493
PMCPMC10897925
OpenAlexW4391248861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.